8th Drug Formulation and Bioavailability

Memo

While still facing evergreen problems with API solubility, formulation professionals are finding new areas for growth in immuno-oncology, regenerative therapies, and controlled release delivery. And beyond purely technical questions, in an increasingly connected workplace the need for improved teamwork is stronger than ever. ExL's 8th Drug Formulation, Solubility and Bioavailability conference is a unique strategic forum where RandD professionals gather to review and rank the latest technological options for drug formulation and delivery, while also bridging the gaps of understanding that may exist between team members. Top Five Reasons to Attend1. Focus on stronger teamwork between formulation and medicinal chemistry2. New insights on continuous manufacturing during early development3. Improved drug delivery options for immuno-oncology and regenerative medicines4. Innovative CNS delivery methods across the blood-brain barrier5. Strategies to select the least painful drug delivery methods **FULL-DAY INTERACTIVE SEMINAR about the development and modeling of amorphous solid dispersions! Featuring in-depth discussions of shelf-life and toxicology challenges, outsourcing decisions, development for nanoparticles and generics - and much more!   Tickets:  https://go.evvnt.com/350341-2?pid=5569  Date and Time: On Monday March 25, 2019 at 8:00 am ends Wednesday March 27, 2019 at 5:00 pm Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States Prices:Conference Only - Early Bird Pricing - Register by February 8th, 2019: USD 1795.0,Conference + Seminar - Early Bird Pricing - Register by February 8, 2019: USD 2495.0,Conference Only - Standard Pricing: USD 1995.0,Conference + Seminar - Standard Pricing: USD 2695.0,Conference Only - Onsite Pricing: USD 2195.0,Conference + Seminar - Onsite Pricing: USD 2895.0 Speakers: Kang-Jye Chou, Scientist, GENENTECH, David Cipolla, Vice President, Research, INSMED, Ann Daugherty, Senior Manager, Drug Delivery, GENENTECH, Eric Dinarello, Senior Scientific Associate, VERTEX PHARMACEUTICALS, Helen Hao Hou, Senior Scientist, Small Molecule Pharmaceutical Sciences, GENENTECH, Keith Horspool, Vice President, Pharmaceutics, BOEHRINGER INGELHEIM, Hyungchul Kim, Fellow, NOVARTIS, Wei Li Postdoctoral, Fellow, Laboratory for Drug Delivery, GEORGIA INSTITUTE OF TECHNOLOGY, Craig McKelvey, Specialty Dosage Formulation Group Lead, MERCK, Eric Munson, Professor and Head, Department of Industrial and Physical Pharmacy, PURDUE UNIVERSITY, Rashmi Nair, Formulation Scientist, DR. REDDY’S, Katharine Odneal, Senior Formulation Scientist, Research and Development, NESHER, Dhaval Patel, Senior Research Investigator, BRISTOL-MYERS SQUIBB, Robert Prud'homme, Professor, Chemical and Biological Engineering, PRINCETON UNIVERSITY, Lilly Roy, Scientist II, VERTEX PHARMACEUTICALS, Aliasger Salem, Head, Division of Pharmaceutics and Translational Therapeutics, UNIVERSITY OF IOWA, Manuel Sanchez-Felix, Senior Fellow, Formulation, NOVARTIS, Wei Xu, Director, Preformulation, MERCK, Tao Zhang, Principal Scientist, Drug Product Design, PFIZER